Issues in Developing Drugs for Primary Brain Tumors: Barriers and Toxicities

Toxicologic Pathology

Volumn 39, Issue 1, 2011, Pages 152-157

  Raizer, Jeffrey ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

brain cancer; chemotherapy; drug development; glioma; nervous system; neuropathology; neurotoxicity; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P;

ANIMAL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TUMOR; DISEASE MODEL; DRUG DEVELOPMENT; DRUG THERAPY; HUMAN; METABOLISM; METHODOLOGY; PATHOLOGY; TOXICITY AND INTOXICATION; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG THERAPY; HUMANS; NEUROTOXICITY SYNDROMES; P-GLYCOPROTEIN;

EID: 79959502381     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310391482     Document Type: Article

References (43)

1. Akabani G. Reardon D. A. Coleman R. E. Wong T. Z. Metzler S. D. Bowsher J. E. Barboriak D. P. Provenzale J. M. Greer K. L. DeLong D. Friedman H. S. Friedman A. H. Zhao X. G. Pegram C. N. McLendon R. E. Bigner D. D. Zalutsky M. R. (2005). Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46, 1042–51.
2. Brandes A. A. Tosoni A. Franceschi E. Sotti G. Frezza G. Amistà P. Morandi L. Spagnolli F. Ermani M. (2009). Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status. J Clin Oncol 27, 1275–9.
3. Bredel M. Scholtens D. M. Harsh G. R. Bredel C. Chandler J. P. Renfrow J. J. Yadav A. K. Vogel H. Scheck A. C. Tibshirani R. Sikic B. I. (2009). A network model of a cooperative genetic landscape in brain tumors. J Am Med Assoc 302, 261–75.
4. Brem H. Ewend M. G. Piantadosi S. Greenhoot J. Burger P. C. Sisti M. (1995). The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neurooncol 26, 111–23.
5. CBTRUS (Central Brain Tumor Registry of the United States) (2010). Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Central Brain Tumor Registry of the United States, Hinsdale, IL. www.cbtrus.org
6. Chamberlain M. C. Glantz M. J. Chalmers L. Van Horn A. Sloan A. E. (2007). Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82, 81–3.
7. DeAngelis L. M. Posner J. B. (2008). Neurologic Complications of Cancer. Oxford University Press, New York, NY.
8. Fine H. A. Dear K. B. Loeffler J. S. Black P. M. Canellos G. P. (1993). Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585–97.
9. J.B., Fiveash, L.L.N.L., Nabors, A.N., Mamelak, N.G., Avgeropoulos, B.L., Guthrie, N.W., Salomon, J., Portnow, R.D., Bucholz, Safety and tolerance of multiple weekly intracavitary injections of, 131, I-chlorotoxin (TM-601): Preliminary results of a prospective clinical trial in patients with recurrent glioblastoma multiforme, J Clin Oncol, Abstract 1555, (2006), 24
10. Friedman H. S. Prados M. D. Wen P. Y. Mikkelsen T. Schiff D. Abrey L. E. Yung W. K. Paleologos N. Nicholas M. K. Jensen R. Vredenburgh J. Huang J. Zheng M. Cloughesy T. (2009). Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27, 4733–40.
11. Futterer S. Grimm S. Chandler J. Muro K. Karagianis A. Marymont M. Raizer J. (2009). Novel MRI changes in patients on Bevacizumab. Neuro Oncol 11, Abstract 473.
12. Gerstner E. R. Frosch M. P. Batchelor T. T. (2010). Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 28, e91–3.
13. Haas-Kogan D. A. Prados M. D. Tihan T. Eberhard D. A. Jelluma N. Arvold N. D. Baumber R. Lamborn K. R. Kapadia A. Malec M. Berger M. S. Stokoe D. (2005). Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97, 880–7.
14. Heimberger A. B. Crotty L. E. Archer G. E. Hess K. R. Wikstrand C. J. Friedman A. H. Friedman H. S. Bigner D. D. Sampson J. H. (2003). Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9, 4247–54.
15. Huse J. T. Holland E. C. (2009). Genetically engineered mouse models of brain cancer and the promise of preclinical testing. Brain Pathol 19, 132–43.
16. Keles G. E. Anderson B. Berger M. S. (1999). The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52, 371–9.
17. Kreisl T. N. Kim L. Moore K. Duic P. Royce C. Stroud I. Garren N. Mackey M. Butman J. A. Camphausen K. Park J. Albert P. S. Fine H. A. (2009). Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27, 740–5.
18. Kuhn J. G. Chang S. M. Wen P. Y. Cloughesy T. F. Greenberg H. Schiff D. Conrad C. Fink K. L. Robins H. I. Mehta M. DeAngelis L. Raizer J. Hess K. Lamborn K. R. Dancey J. Prados M. D. the North American Brain Tumor Consortium, and the National Cancer Institute (2007). Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 13, 7401–6.
19. Kunwar S. Chang S. Westphal M. Vogelbaum M. Sampson J. Barnett G. Shaffrey M. Ram Z. Piepmeier J. Prados M. Croteau D. Pedain C. Leland P. Husain S. R. Joshi B. H. Puri R. K. and the PRECISE Study Group (2010). Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol 12, 871–81.
20. Lacroix M. Abi-Said D. Fourney D. R. Gokaslan Z. L. Shi W. DeMonte F. Lang F. F. McCutcheon I. E. Hassenbusch S. J. Holland E. Hess K. Michael C. Miller D. Sawaya R. (2001). A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 95, 190–8.
21. Lai R. Recht L. R. Reardon D. A. Paleologos N. Groves M. D. Rosenfeld M. R. Meech S. Davis T. A. Pavlov D. Sampson J. H. (2010). Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). J Clin Oncol 28, Abstract 2014.
22. Lassman A. B. Rossi M. R. Raizer J. J. Abrey L. E. Lieberman F. S. Grefe C. N. Lamborn K. Pao W. Shih A. H. Kuhn J. G. Wilson R. Nowak N. J. Cowell J. K. DeAngelis L. M. Wen P. Gilbert M. R. Chang S. Yung W. A. Prados M. Holland E. C. (2005). Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11, 7841–50.
23. Lee J. C. Beroukhim R. Huang J. H. Feng W. L. DeBiasi R. M. Yoshimoto K. King J. C. Nghiemphu P. Yuza Y. Xu Q. Greulich H. Thomas R. K. Paez J. G. Peck T. C. Linhart D. J. Glatt K. A. Getz G. Onofrio R. Ziaugra L. Levine R. L. Gabriel S. Kawaguchi T. O’Neill K. Khan H. Liau L. M. Nelson S. F. Rao P. N. Mischel P. Pieper R. O. Cloughesy T. Leahy D. J. Sellers W. R. Sawyers C. L. Meyerson M. Mellinghoff I. K. (2006). Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 3, e485.
24. Louis D. N. Ohgaki H. Wiestler O. D. Cavenee W. K. (2007). WHO Classification of Tumours of the Central Nervous System. WHO Press, New York, NY.
25. Mellinghoff I. K. Cloughesy T. F. Mischel P. S. (2007). PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 13, 378–81.
26. Mellinghoff I. K. Wang M. Y. Vivanco I. Haas-Kogan D. A. Zhu S. Dia E. Q. Lu K. V. Yoshimoto K. Huang J. H. Chute D. J. Riggs B. L. Horvath S. Liau L. M. Cavenee W. K. Rao P. N. Beroukhim R. Peck T. C. Lee J. C. Sellers W. R. Stokoe D. Prados M. Cloughesy T. F. Sawyers C. L. Mischel P. S. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353, 2012–24.
27. Miller D. F. Bay J. W. Lederman R. J. Purvis J. D. Rogers L. R. Tomsak R. L. (1985). Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 92, 402–6.
28. Nieder C. Mehta M. P. Jalali R. (2009). Combined radio- and chemotherapy of brain tumours in adult patients. Clin Oncol (R Coll Radiol) 21, 515–24.
29. Ostermann S. Csajka C. Buclin T. Leyvraz S. Lejeune F. Decosterd L. A. Stupp R. (2004). Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10, 3728–36.
30. Parney I. F. Kunwar S. McDermott M. Berger M. Prados M. Cha S. Croteau D. Puri R. K. Chang S. M. (2005). Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102, 267–75.
31. Portnow J. Badie B. Chen M. Liu A. Blanchard S. Synold T. W. (2009). The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation. Clin Cancer Res 15, 7092–8.
32. Raizer J. J. Abrey L. E. Lassman A. B. Chang S. M. Lamborn K. R. Kuhn J. G. Yung W. K. Gilbert M. R. Aldape K. A. Wen P. Y. Fine H. A. Mehta M. DeAngelis L. M. Lieberman F. Cloughesy T. F. Robins H. I. Dancey J. Prados M. D. and the North American Brain Tumor Consortium (2010a). A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol 12, 87–94.
33. Raizer J. J. Abrey L. E. Lassman A. B. Chang S. M. Lamborn K. R. Kuhn J. G. Yung W. K. Gilbert M. R. Aldape K. A. Wen P. Y. Fine H. A. Mehta M. DeAngelis L. M. Lieberman F. Cloughesy T. F. Robins H. I. Dancey J. Prados M. D. and the North American Brain Tumor Consortium (2010b). A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol 12, 95–103.
34. Rosenblum M. K. Delattre J. Y. Walker R. W. Shapiro W. R. (1989). Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: A pathological study. J Neurooncol 7, 269–81.
35. Sabel M. Giese A. (2008). Safety profile of carmustine wafers in malignant glioma: A review of controlled trials and a decade of clinical experience. Curr Med Res Opin. [Epub ahead of print].
36. Stewart L. H. Brush J. P. (2002). Magnetic resonance imaging for urinary incontinence. Curr Opin Urol 12, 133–6.
37. Stommel J. M. Kimmelman A. C. Ying H. Nabioullin R. Ponugoti A. H. Wiedemeyer R. Stegh A. H. Bradner J. E. Ligon K. L. Brennan C. Chin L. DePinho R. A. (2007). Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318, 287–90.
38. Stupp R. Mason W. P. van den Bent M. J. Weller M. Fisher B. Taphoorn M. J. Belanger K. Brandes A. A. Marosi C. Bogdahn U. Curschmann J. Janzer R. C. Ludwin S. K. Gorlia T. Allgeier A. Lacombe D. Cairncross J. G. Eisenhauer E. Mirimanoff R. O. the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, and the National Cancer Institute of Canada Clinical Trials Group (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352, 987–96.
39. van den Bent M. J. Brandes A. A. Rampling R. Kouwenhoven M. C. Kros J. M. Carpentier A. F. Clement P. M. Frenay M. Campone M. Baurain J. F. Armand J. P. Taphoorn M. J. Tosoni A. Kletzl H. Klughammer B. Lacombe D. Gorlia T. (2009). Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27, 1268–74.
40. Videnovic A. Semenov I. Chua-Adajar R. Baddi L. Blumenthal D. T. Beck A. C. Simuni T. Futterer S. Gradishar W. Tellez C. Raizer J. J. (2005). Capecitabine-induced multifocal leukoencephalopathy: A report of five cases. Neurology 65, 1792–4.
41. Walker M. D. Green S. B. Byar D. P. Alexander E. Jr. Batzdorf U. Brooks W. H. Hunt W. E. MacCarty C. S. Mahaley M. S. Jr. Mealey J. Jr. Owens G. Ransohoff J. II Robertson J. T. Shapiro W. R. Smith K. R. Jr. Wilson C. B. Strike T. A. (1980). Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303, 1323–9.
42. Westphal M. Hilt D. C. Bortey E. Delavault P. Olivares R. Warnke P. C. Whittle I. R. Jääskeläinen J. Ram Z. (2003). A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5, 79–88.
43. Wick W. Hartmann C. Engel C. Stoffels M. Felsberg J. Stockhammer F. Sabel M. C. Koeppen S. Ketter R. Meyermann R. Rapp M. Meisner C. Kortmann R. D. Pietsch T. Wiestler O. D. Ernemann U. Bamberg M. Reifenberger G. von Deimling A. Weller M. (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27, 5874–80.